GSK reveals two-dose Cervarix data
This article was originally published in Scrip
GlaxoSmithKline has presented the Phase III data for its cervical cancer vaccine Cervarix (human papillomavirus (types 16 and 18) vaccine, recombinant) that supported its recent EU expanded approval application for use in a two-dose, rather than three-dose, schedule in some recipients.
You may also be interested in...
Circassia is returning the US rights to two COPD drugs to AstraZeneca as it admits it cannot meet its debt payments from the deal.
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.
Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.